Oragenics, Inc

Oragenics, Inc. is a development-stage company focused on creating innovative medical technologies to address critical unmet needs. Their primary areas of focus include developing drugs, therapies, and vaccines through intranasal delivery, fighting infectious diseases like coronaviruses and multidrug-resistant organisms, and tackling brain-related illnesses and injuries. Their mission is to develop life-enhancing medical products that offer clinical advantages and address unmet needs.

Oragenics has a diverse portfolio of promising product candidates. Their lead product, Terra CoV-2, is an intranasal vaccine candidate designed to prevent COVID-19 and future variants. They also have a lantibiotics program, which focuses on developing a novel class of antibiotics to combat antibiotic-resistant bacteria. In addition, they recently acquired assets related to proprietary neurological drug therapies, including candidates for treating concussion and Niemann Pick Disease Type C.

Oragenics, Inc. is a development-stage company dedicated to creating innovative medical technologies that address unmet clinical needs and have significant market potential. They focus on developing drugs, therapies, and vaccines through intranasal delivery, with a particular emphasis on combating infectious diseases like coronaviruses and multidrug-resistant organisms. Their mission is to create life-enhancing medical products that offer a clinical advantage and provide solutions to critical healthcare challenges.

Oragenics promotes a culture of excellence built by passionate and talented individuals driven by success. The company fosters a collaborative environment where employees work together to make a difference in the lives of others.